Detalles de la búsqueda
1.
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Lancet Oncol
; 16(7): 787-94, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26028518
2.
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.
Clin Genitourin Cancer
; 21(5): 615.e1-615.e8, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37263910
3.
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.
Eur J Cancer
; 48(2): 209-17, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22119204
4.
Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study.
Clin Genitourin Cancer
; 7(2): E28-33, 2009 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-19692319
Resultados
1 -
4
de 4
1
Próxima >
>>